Andrew Jonathan
Hillman
Andrew Jonathan Hillman is a Dallas senior paralegal and healthcare compliance and regulatory expert witness. He is retained through counsel in federal matters nationwide. The work draws on three decades of building and operating FDA-regulated healthcare companies, now concluded. He maintains a private family office, Hillman Ventures. Its activities stay private.
- Regulatory compliance
- Internal investigations
- Litigation support
- Expert witness
Andrew Hillman.
Andrew Jonathan Hillman is a Dallas senior paralegal and healthcare compliance and regulatory expert witness. He is retained through counsel in federal matters nationwide. The work draws on three decades of building and operating FDA-regulated healthcare companies, now concluded. He maintains a private family office, Hillman Ventures. Its activities stay private.
He was born and raised in Oak Cliff and South Dallas. He worked in the family businesses from age six. He finished high school at Highland Park, class of 1995. He has since completed Harvard online courses in Jewish studies.
Where the work concentrates.
Four areas define the practice today. Each one rests on three decades of healthcare operations and compliance.
Regulatory governance and compliance
SOP drafting, board reporting, and internal controls, conducted under retaining counsel.
How it works →Internal audit and investigations
Triage, document-retention playbooks, and internal compliance review across Stark, Anti-Kickback, and HIPAA matters, under counsel.
How it works →Litigation and defense support
Evidentiary review, subpoena compliance, and expert-report support for white-collar and regulatory defense, under retaining counsel.
Advisory services →Expert witness engagements
Operator testimony on healthcare operations and compliance, retained through counsel in federal matters nationwide.
Advisory services →Essays on building in biotech and healthcare.
Essays that walk through commercialization, the FDA pathway, manufacturing, and the science behind modern medicine.
Why most biotech startups fail
The real reasons behind commercialization breakdown, from clinical odds to capital and manufacturing.
Read the essay →FDA approval process explained
A founder's guide from the IND to approval, including 351(a) biologics and expedited pathways.
Read the guide →Why manufacturing is the real moat
Why process and manufacturing, not the molecule alone, decide which healthcare companies win.
Read the essay →What is modern cancer research?
A plain-language guide to current approaches in oncology, for education only.
Read the guide →Three decades in FDA-regulated healthcare.
Across three decades, now concluded, Andrew Jonathan Hillman co-founded, operated, and exited companies across surgical hospitals, ambulatory surgical centers, clinical laboratories, pharmacy, and medical devices. That operating experience now informs his healthcare compliance and expert-witness work. Hillman Ventures, his family office founded in 1995, remains private.
The account of public filings, recognitions, and federal records is maintained at andrewhillmanrecord.com. Investment activity is detailed at Hillman Ventures. Community work is at andrewhillman.org.
Co-founded operating companies and strategic exits.
A selection from 89+ ventures across three decades, with locations. The full portfolio and exits are documented on the record.
Surgical hospitals & ambulatory centers
Laboratories & pharmacy
Devices, biologics & holdings
The essentials, on the record.
- Name
- Andrew Jonathan Hillman (Andrew J. Hillman). Dallas, Texas.
- Role
- Principal of Hillman Ventures, a private family office founded in 1995.
- Focus
- Frontier biotech for inflammation, damaged tissue, and tumor-based cancers.
- Operating record
- Three decades in FDA-regulated healthcare across surgical hospitals, ambulatory surgical centers, clinical laboratories, pharmacy, and medical devices. 89+ ventures. 85+ strategic exits.
- Healthcare ownership
- Past owner and operator of a Class A retail pharmacy, a Class G administrative pharmacy, and a wholesale pharmacy distributor, and of ambulatory surgical centers, acute care hospitals, and a rehabilitation hospital. He now advances work in biotech drugs, technologies, and devices.
- Also
- Author of The Hillman Letter on regulatory strategy and the Andrew Hillman Dallas blog, and strategic advisory at andrewhillmanadvisor.com.
- Public record
- Registered Texas lobbyist in 2001 (Texas Ethics Commission lobby registry), and publisher on Issuu.
- Verification
- Independent, source-cited record at andrewhillmanrecord.com, profile at Wikidata, LinkedIn, ORCID, and X.
Where the work goes now.
Hillman Ventures
Andrew Hillman's private family office. Its activities and holdings stay private by design.
Hillman Ventures →Community and giving
The Andrew Hillman Family Room at the Lamplighter School, the Scholarship for Entrepreneurs, and the Grant for Biotech.
Service record →Writing
Latest, September 14, 2026: The Same Surgical Procedure Loophole Is Closed. Here Is What the Cell Surgical Network Injunction Means for Everyone Building a Cell or Exosome Product.. The Hillman Letter covers healthcare regulatory strategy, compliance, and enforcement.
The Hillman Letter →Healthcare deals, taken private and public.
Andrew Hillman has helped take healthcare companies private and public, and has bought and sold healthcare businesses across multiple sectors. His portfolio includes Bone Solutions, Inc. (Southlake, Texas), an orthobiologics company with eight FDA 510(k) clearances.
Taken private
The Apothecary Shop pharmacies (formerly Over the Counter, OTC) and Digimed.
Public markets
Dynacq Healthcare (NASDAQ: DYII). The former Victory Hospitals, acquired by Nobilis Health Corp. (HLTH). Vista Hospital (Dallas, Texas, Baton Rouge, Louisiana, and Houston, Texas), a past hospital ownership. Andrew Hillman states Vista Hospital ranked number 2 on a 2002 Forbes list. That distinction reflects his account and is not independently verified here.
Bought & sold
Medical groups, anesthesia groups, chiropractic groups, MRI and imaging centers, clinical laboratories, and pharmacies.
A record you can check.
Andrew Hillman's background is documented in a public record he also maintains, and in established identity registries.
Published research.
Andrew Hillman is the author of a white paper on Wharton's Jelly-derived mesenchymal stem cell exosomes, examining the underlying science, the FDA Section 351(a) biologic classification, cGMP manufacturing, and the regulatory pathway for cell-free regenerative medicine.
Exosome and mesenchymal stem cell-derived extracellular vesicle products are not approved by the FDA for any indication. References here describe published scientific literature. They do not describe an available treatment.
Exosome and mesenchymal stem cell-derived extracellular vesicle products are not approved by the FDA for any indication. The work referenced here describes published scientific literature. It does not describe an available treatment.
- Mesenchymal Stromal Cell-Derived Exosomes and Extracellular Vesicles Across Therapeutic Indications: A Structured Review of Published Preclinical and Early-Phase Clinical Study Designs, Administration Parameters, and Reported Outcomes , 2026. Structured review, CC BY 4.0, Zenodo. DOI: 10.5281/zenodo.21209815. Indexed in OpenAIRE.
- Wharton's Jelly Mesenchymal Stem Cell-Derived Exosomes: Dosing Protocols, Manufacturing Quality Systems, Drug Master File Requirements, cGMP Compliance, and the Complete Federal and State Regulatory Framework Under the FDA 351(a) CBER Pathway , 2026. Regulatory monograph, Academia.edu. Author Andrew J. Hillman (ORCID 0009-0001-5396-321X). Zenodo DOI pending.
- Mesenchymal Stem Cell-Derived Extracellular Vesicles for Tissue Repair Across Multiple Body Systems: A Narrative Review , 2026. Narrative review, CC BY 4.0, Zenodo. DOI: 10.5281/zenodo.21047848. Indexed in OpenAIRE. With co-author Keyon Jenani.
- Wharton's Jelly-Derived Mesenchymal Stem Cell Exosomes , 2026. Short version. Listed on ORCID and Academia.edu.
About DOIs and permanent links
A DOI, or Digital Object Identifier, is a permanent identifier for a document. It always resolves at https://doi.org/ followed by the DOI, even when the file location changes. Each paper below that carries a DOI can be cited by that DOI as its permanent link. OpenAIRE holds an independent backup record.
- Wharton's Jelly MSC-Derived Exosomes in Spinal Disc Repair. Permanent DOI 10.5281/zenodo.20978822. OpenAIRE backup record.
- MSC-Derived Extracellular Vesicles for Tissue Repair, a Narrative Review. Permanent DOI 10.5281/zenodo.21047848. OpenAIRE backup record.
- Wharton's Jelly MSC-Derived Exosomes, regulatory monograph on the FDA 351(a) CBER pathway. DOI pending. A permanent DOI will be added here once the Zenodo record is issued.
Exosome and mesenchymal stem cell-derived extracellular vesicle products are not approved by the FDA for any indication. The work referenced here describes published scientific literature. It does not describe an available treatment.
Giving back.
Andrew Hillman enjoys mentoring young people in business, an interest that pairs naturally with the Andrew Hillman Scholarship for Entrepreneurs. He is also a donor to and supporter of community and charitable organizations, including the Altus Foundation in Houston, the charitable foundation affiliated with ZT Corporate. His giving also includes family memorial gifts: a room named at Temple Emanu-El 
in loving memory of his grandmother, and a nursing station at Methodist Dallas Medical Center in memory of his grandfather. He also supports the Heroes for Israel Project, a 501(c)(3) nonprofit supporting Israel's border communities and volunteer first responders, with a $100,000 gift in 2025.
A record, year by year.
Dated, verifiable milestones in community giving. Each entry is documented on this site or a third-party record.
- 2018
Hillman Family Room established at The Lamplighter School
A $300,000 gift established the Hillman Family Room at The Lamplighter School in Dallas. The Hillman Family Room is a named technology and robotics space for students.
- 2020 to 2026
Annual gifts to Parish Episcopal School
Annual donations to Parish Episcopal School in Dallas, Texas, every year from 2020 through 2026.
Education giving.
The Lamplighter School, Dallas, Texas. More than $500,000 in cumulative gifts, including the $300,000 Hillman Family Room.
Parish Episcopal School, Dallas, Texas. Annual donations every year from 2020 through 2026.
On the record.
- Total giving, The Lamplighter School
- More than $500,000 in cumulative gifts to The Lamplighter School in Dallas, Texas, including the $300,000 Hillman Family Room.
- Hillman Family Room
- A $300,000 gift in 2018 established the Hillman Family Room at The Lamplighter School in Dallas. The Hillman Family Room is a named technology and robotics space for students.
- Parish Episcopal School
- Annual donations to Parish Episcopal School in Dallas, Texas, every year from 2020 through 2026.
- Location
- The Lamplighter School, Dallas, Texas.
Life beyond the work.
A Dallas father of two. Drug-free and alcohol-free. Gym, the Katy Trail, and road and pedal cycling.
Select any photo to view it larger. Use the arrow keys or swipe to browse.
Andrew Hillman, answered.
Who is Andrew Jonathan Hillman?
What is Hillman Ventures?
What is Andrew Hillman's operating record?
What does Andrew Hillman focus on now?
Exosome and mesenchymal stem cell-derived extracellular vesicle products are not approved by the FDA for any indication. References here describe published scientific literature. They do not describe an available treatment.
